Edwin E. Jeng
YOU?
Author Swipe
View article: Supplementary Table S5 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Table S5 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Preliminary Pharmacokinetic Parameters of ABBV-011 ADC Following IV Infusion of ABBV-011 1 mg/kg in Cycle 1 (n=40)
View article: Supplementary Figure S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Figure S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Preclinical efficacy study with xenograft models derived from patients with SCLC
View article: Data from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Data from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Purpose:Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated in a phase I study (NCT03639194) in patients with …
View article: Supplementary Table S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Table S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Patient Disposition
View article: Supplementary Table S3 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Table S3 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Time to Onset of First Hepatotoxicity Event
View article: Supplementary Figure S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Figure S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Mean (± SD) preliminary ABBV-011 ADC concentration-time profiles following IV infusion of ABBV-011 (0.3 to 2.0 mg/kg) in cycle 1
View article: Supplementary Table S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Table S2 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Representativeness of Study Participants
View article: Supplementary Table S4 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Table S4 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Most Frequent Treatment-Related Adverse Events
View article: Supplementary Table S6 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Table S6 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Overview of Treatment Response by Line of Treatment and Platinum Sensitivity
View article: Supplementary Methods S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
Supplementary Methods S1 from A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Definition of dose-limiting toxicities and methods for patient-derived xenograft studies
Phase 3, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared with Rituximab Plus Gemcitabine and Oxaliplatin in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Open
Introduction: Outcomes for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) are poor, especially for those ineligible for autologous stem cell transplantation. Despite the high response rate with chimeric antig…
Fixed-Duration Epcoritamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results from Arm 1 of the Epcore NHL-5 Trial Open
Introduction: Patients with relapsed or refractory (R/R) DLBCL have a poor prognosis, even if treated with salvage chemotherapy and autologous stem cell transplantation (ASCT). CAR T therapy provides long-term remission in only 40% of pati…
View article: A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer
A Phase I First-in-Human Study of ABBV-011, a Seizure-Related Homolog Protein 6–Targeting Antibody–Drug Conjugate, in Patients with Small Cell Lung Cancer Open
Purpose: Seizure-related homolog protein 6 (SEZ6) is a novel target expressed in small cell lung cancer (SCLC). ABBV-011, a SEZ6-targeted antibody conjugated to calicheamicin, was evaluated in a phase I study (NCT03639194) in patients with…
Data from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Activating mutations in RAS GTPases drive many cancers, but limited understanding of less-studied RAS interactors, and of the specific roles of different RAS interactor paralogs, continues to limit target discovery. We developed a multista…
Data from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Activating mutations in RAS GTPases drive many cancers, but limited understanding of less-studied RAS interactors, and of the specific roles of different RAS interactor paralogs, continues to limit target discovery. We developed a multista…
Supplementary Table 4 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Results from the single-target sgRNA screen in A549-Cas9 cells. The columns are as follows. Symbol : HUGO gene symbol ; EnsemblID : EnsEMBL identifier ; GeneID : Entrez Gene ID ; GeneInfo : Name of protein encoded by the gene ; Localizatio…
Supplementary Table 7 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Results from the "Paralog" sublibrary screen. Different metrics are reported on each of the three tabs of the spreadsheet as indicated. GI-T-Score : GIT Score; MWU Adj Pval: FDR of Mann-Whitney U Test p-value after Benjamini-Hochberg corre…
Supplementary Table 2 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
This table lists genes whose protein products were identified by AP/MS experiments in HEK293 cells or A549 cells on the indicated sheets. The columns are as follows. Bait: bait protein (gene-wise); Prey, prey protein (gene-wise); Backgroun…
Supplementary Table 4 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Results from the single-target sgRNA screen in A549-Cas9 cells. The columns are as follows. Symbol : HUGO gene symbol ; EnsemblID : EnsEMBL identifier ; GeneID : Entrez Gene ID ; GeneInfo : Name of protein encoded by the gene ; Localizatio…
Supplementary Table 3 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
This spreadsheet contains 6 tabs, with each tab corresponding to a cell line and GO namespace. For each indicated bait (columns), all hits detected with FDR{less than or equal to}0.05 were searched for enrichment for the indicated term (ro…
Supplementary Table 8 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Table of sgRNA sequences.
Supplementary Data from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Supplementary Methods, Descriptions of Supplementary Tables, Supplementary Figures, Supplementary References
Supplementary Table 3 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
This spreadsheet contains 6 tabs, with each tab corresponding to a cell line and GO namespace. For each indicated bait (columns), all hits detected with FDR{less than or equal to}0.05 were searched for enrichment for the indicated term (ro…
Supplementary Table 5 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Results from the first pairwise sgRNA screen in A549-Cas9 and H23-Cas9 cells. Columns are as in the previous table, except that they refer to Gene A or Gene B as indicated, where the symbol for GeneA comes alphabetically before the symbol …
Supplementary Table 7 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Results from the "Paralog" sublibrary screen. Different metrics are reported on each of the three tabs of the spreadsheet as indicated. GI-T-Score : GIT Score; MWU Adj Pval: FDR of Mann-Whitney U Test p-value after Benjamini-Hochberg corre…
Supplementary Table 2 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
This table lists genes whose protein products were identified by AP/MS experiments in HEK293 cells or A549 cells on the indicated sheets. The columns are as follows. Bait: bait protein (gene-wise); Prey, prey protein (gene-wise); Backgroun…
Supplementary Table 1 from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Primers for quickchange mutagenesis of the indicated bait proteins used in AP/MS experiments.
Supplementary Data from Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and Susceptibilities Open
Supplementary Methods, Descriptions of Supplementary Tables, Supplementary Figures, Supplementary References